AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3135734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG)
Number of subjects: 40
Study 3135734 — intervention group
Group type: COMPARATOR
Intervention: Intravenous nitroprusside (NTP)
Number of subjects: 40
Study 31562059 — intervention group
Group type: EXPERIMENTAL
Intervention: bCPAP
Number of subjects: 644
Study 31562059 — intervention group
Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 644
Study 29308591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ELI‐200 (30‐mg oxycodone hydrochloride/3‐mg naltrexone HCl)
Number of subjects: 44
Study 29308591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxycodone immediate release (30‐mg oxycodone HCl)
Number of subjects: 44
Study 29308591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29308591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ELI‐200 (30mg/3mg)
Number of subjects: 44
Study 29308591 — intervention group
Group type: COMPARATOR
Intervention: Fixed placebo
Number of subjects: 44
Study 25192833 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 93
Study 25192833 — intervention group
Group type: COMPARATOR
Intervention: CNI
Number of subjects: 93
Study 22842905 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 94
Study 22842905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 21507067 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 1.25 ATA with 32% oxygen for 1 h/day, three times per week for males; two times per week for females.
Number of subjects: 0
Study 21507067 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 1.25 ATA with 32% oxygen for 1 h/day, two times per week for females.
Number of subjects: 0
Study 19198708 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dextromethorphan (45 mg)
Number of subjects: 76
Study 19198708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 17167382 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent advances in understanding diastolic heart failure (DHF)
Number of subjects: 0
Study 15005303 — intervention group
Group type: EXPERIMENTAL
Intervention: Determined compliance in SAH group
Number of subjects: 0
Study 15005303 — intervention group
Group type: COMPARATOR
Intervention: Determined compliance in controlled group
Number of subjects: 0
Study 15005303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity (PWV) using maximum of first derivative of pressure waveform
Number of subjects: 0
Study 11372025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nvp and 3TC mutations detected frequently at virologic failure
Number of subjects: 0
Study 11372025 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintained on study regimen after virologic failure
Number of subjects: 0
Study 11372025 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline drug resistance mutations
Number of subjects: 0
Study 11372025 — intervention group
Group type: EXPERIMENTAL
Intervention: Zdv, ddI, and ddC mutations
Number of subjects: 0
Study 11372025 — intervention group
Group type: EXPERIMENTAL
Intervention: Rtv and Nfv mutations
Number of subjects: 0
Study 9656393 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether (150 and 100 mg) with mefloquine (750 and 500 mg)
Number of subjects: 99
Study 9656393 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (150 and 100 mg) with mefloquine (750 and 500 mg)
Number of subjects: 99
Study 9656393 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether with mefloquine
Number of subjects: 99
Study 9656393 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate with mefloquine
Number of subjects: 99
Study 8386603 — intervention group
Group type: EXPERIMENTAL
Intervention: d-sotalol
Number of subjects: 3
Study 8386603 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 3
Study 8386603 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3
Study 3112428 — intervention group
Group type: EXPERIMENTAL
Intervention: 85-cm open-ended, unweighted nasogastric feeding tube (Prima, Portex UK)
Number of subjects: 403
Study 3112428 — intervention group
Group type: COMPARATOR
Intervention: 91-cm 3.0-g weighted tube (Entriflex, Biosearch, Raritan, NJ)
Number of subjects: 403
Study 3112428 — intervention group
Group type: EXPERIMENTAL
Intervention: New polyurethane nasogastric feeding tubes (one weighted and one unweighted)
Number of subjects: 403
Study 3112428 — intervention group
Group type: COMPARATOR
Intervention: Widely used PVC unweighted open-ended tube
Number of subjects: 403
Study 30003367 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood
Number of subjects: 3
Study 30003367 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood
Number of subjects: 3
Study 30003367 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral mood
Number of subjects: 3
Study 27687347 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (4 mg/kg)
Number of subjects: 50
Study 27687347 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (0.05 mg/kg) and Atropine (0.01 mg/kg)
Number of subjects: 50
Study 24742955 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone (E; n = 95)
Number of subjects: 284
Study 24742955 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary‐induced weight loss (D; n = 88)
Number of subjects: 284
Study 24742955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dietary‐induced weight loss and exercise (D + E; n = 101)
Number of subjects: 284
Study 22520138 — intervention group
Group type: EXPERIMENTAL
Intervention: PRV (pentavalent rotavirus vaccine)
Number of subjects: 1308
Study 22520138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1308
Study 22520138 — intervention group
Group type: EXPERIMENTAL
Intervention: PRV
Number of subjects: 1308
Study 20019677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (<30 g/day)
Number of subjects: 144
Study 20019677 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (≤30% of calories from fat with a deficit of 500 kcal/day)
Number of subjects: 144
Study 18807900 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction (LTS)
Number of subjects: 40
Study 18807900 — intervention group
Group type: COMPARATOR
Intervention: Proseal Laryngeal Mask Airway (PLMA)
Number of subjects: 40
Study 15810646 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin, 200 mg bid (Group R1: 39 pts)
Number of subjects: 170
Study 15810646 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin, 400 mg bid (Group R2: 43 pts)
Number of subjects: 170
Study 15810646 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine, 400 mg bid (Group M1: 40 pts)
Number of subjects: 170
Study 15810646 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine, 800 mg bid (Group M2: 48 pts)
Number of subjects: 170
Study 12375668 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic calcium (Ca) chloride or Ca gluconate at a dose linked to citrate infusion rate (1.0‐2.2 mg/kg/min)
Number of subjects: 315
Study 12375668 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic calcium (Ca) chloride
Number of subjects: 315
Study 12375668 — intervention group
Group type: COMPARATOR
Intervention: Citrate anticoagulation without prophylactic calcium
Number of subjects: 315
Study 12375668 — intervention group
Group type: COMPARATOR
Intervention: Citrate administration
Number of subjects: 315
Study 10100361 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact laser vaporization (CLV)
Number of subjects: 50
Study 10100361 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 50
Study 7842770 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (10 mg/m2 of body)
Number of subjects: 12
Study 7842770 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (0.3 mg/m2 of body)
Number of subjects: 12
Study 7842770 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 12
Study 1974124 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (injected intradermally, 2 min prior to challenge)
Number of subjects: 0
Study 1974124 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (injected intradermally, 2 min prior to challenge)
Number of subjects: 0
Study 1974124 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Formoterol and Terbutaline
Number of subjects: 0
Study 651283 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lanatosid C in saline
Number of subjects: 0
Study 651283 — intervention group
Group type: COMPARATOR
Intervention: Corresponding volume of saline (placebo)
Number of subjects: 0
Study 31923712 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Pelvic Radiation Therapy (WPRT, 68 Gy/25# to prostate and 50 Gy/25# to pelvis)
Number of subjects: 224
Study 31923712 — intervention group
Group type: COMPARATOR
Intervention: Prostate Only Radiation Therapy (PORT, 68 Gy/25# to prostate)
Number of subjects: 224
Study 31923712 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Pelvic Radiation Therapy (WPRT)
Number of subjects: 224
Study 31923712 — intervention group
Group type: COMPARATOR
Intervention: Prostate Only Radiation Therapy (PORT)
Number of subjects: 224
Study 31923712 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Pelvic Radiation Therapy (WPRT) and Prostate Only Radiation Therapy (PORT)
Number of subjects: 224
Study 31429019 — intervention group
Group type: EXPERIMENTAL
Intervention: Shave group
Number of subjects: 181
Study 31429019 — intervention group
Group type: COMPARATOR
Intervention: No-shave group
Number of subjects: 181
Study 31429019 — intervention group
Group type: EXPERIMENTAL
Intervention: Shave group (C-E cup breasts)
Number of subjects: 181
Study 31429019 — intervention group
Group type: COMPARATOR
Intervention: No-shave group (C-E cup breasts)
Number of subjects: 181
Study 31429019 — intervention group
Group type: EXPERIMENTAL
Intervention: Shave group (A-B cup breasts)
Number of subjects: 181
Study 31429019 — intervention group
Group type: COMPARATOR
Intervention: No-shave group (A-B cup breasts)
Number of subjects: 181
Study 28810731 — intervention group
Group type: EXPERIMENTAL
Intervention: EhimNTf2/water mixtures at 2:1 and 1:1 concentrations
Number of subjects: 0
Study 28810731 — intervention group
Group type: EXPERIMENTAL
Intervention: EmimNTf2/water mixtures
Number of subjects: 0
Study 28810731 — intervention group
Group type: EXPERIMENTAL
Intervention: EhimNTf2/water mixtures
Number of subjects: 0
Study 28810731 — intervention group
Group type: EXPERIMENTAL
Intervention: FT-IR spectra analysis
Number of subjects: 0
Study 28810731 — intervention group
Group type: EXPERIMENTAL
Intervention: OHD-OKE experiments
Number of subjects: 0
Study 27181565 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 672
Study 27181565 — intervention group
Group type: COMPARATOR
Intervention: PCI with DES
Number of subjects: 672
Study 25066366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy
Number of subjects: 0
Study 25066366 — intervention group
Group type: COMPARATOR
Intervention: Collaborative care (three-session psycho-educational intervention)
Number of subjects: 0
Study 25066366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychotherapy and Collaborative care
Number of subjects: 0
Study 23235363 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg and aliskiren 300 mg
Number of subjects: 18
Study 23235363 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg and eplerenone 50 mg
Number of subjects: 18
Study 23235363 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 160 mg as monotherapy
Number of subjects: 18
Study 19843596 — intervention group
Group type: COMPARATOR
Intervention: VCPAP
Number of subjects: 30
Study 19843596 — intervention group
Group type: EXPERIMENTAL
Intervention: BCPAP
Number of subjects: 30
Study 18591363 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month fruit and vegetable intervention
Number of subjects: 1277
Study 18591363 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1277
Study 18591363 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintainers of 5 or more servings per day
Number of subjects: 1277
Study 18591363 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed to progress
Number of subjects: 1277
Study 16078963 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer drugs
Number of subjects: 6256
Study 16078963 — intervention group
Group type: COMPARATOR
Intervention: Older agents
Number of subjects: 6256
Study 12269790 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of modafinil
Number of subjects: 10
Study 12269790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10025924 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFNalpha) 13.5 x 10(6) units per week in divided doses
Number of subjects: 35
Study 7741245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7741245 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 48
Study 7741245 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 48
Study 7741245 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants plus Vitamin D
Number of subjects: 48
Study 1434726 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 321
Study 1434726 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 321
Study 1434726 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 321
Study 3902105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide 2 mg or 6 mg
Number of subjects: 106
Study 3902105 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine 25 mg or 75 mg
Number of subjects: 106
Study 3902105 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of pimozide and thioridazine
Number of subjects: 106
Study 3902105 — intervention group
Group type: COMPARATOR
Intervention: Retrospective placebo group
Number of subjects: 106
Study 30810462 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel bulking agent (Bulkamid®)
Number of subjects: 291
Study 30810462 — intervention group
Group type: COMPARATOR
Intervention: Collagen gel (Contigen®)
Number of subjects: 291
Study 30268057 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitation (Healthy Families New York)
Number of subjects: 104
Study 30268057 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visitation)
Number of subjects: 104
Study 26306566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing β-hydroxy-β-methylbutyrate (HMB), glutamine and arginine (3g HMB, 14g glutamine, 14g arginine daily for 6 months)
Number of subjects: 31
Study 26306566 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo
Number of subjects: 31
Study 24622685 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided games (SSG)
Number of subjects: 19
Study 24622685 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 19
Study 24622685 — intervention group
Group type: COMPARATOR
Intervention: Both SSG and HIIT
Number of subjects: 19
Study 23429675 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (n = 176)
Number of subjects: 351
Study 23429675 — intervention group
Group type: COMPARATOR
Intervention: Brief intervention (n = 175)
Number of subjects: 351
Study 23429675 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup receiving multidisciplinary intervention (n = 60)
Number of subjects: 351
Study 23429675 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation study (n = 28)
Number of subjects: 351
Study 21352670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV)
Number of subjects: 22
Study 21352670 — intervention group
Group type: COMPARATOR
Intervention: Traditional standard chest physical therapy
Number of subjects: 22
Study 19586546 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteosynthesis with angle-stable plate
Number of subjects: 162
Study 19586546 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary hemiarthroplasty
Number of subjects: 162
Study 19586546 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical management
Number of subjects: 162
Study 17725180 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg capsules (Ranbaxy Laboratories Ltd.)
Number of subjects: 40
Study 17725180 — intervention group
Group type: COMPARATOR
Intervention: Zerit 40 mg capsules (Bristol-Myers Squibb)
Number of subjects: 40
Study 15195000 — intervention group
Group type: EXPERIMENTAL
Intervention: [123I]-MIBG wash out rate (WOR)
Number of subjects: 11
Study 15195000 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (higher WOR)
Number of subjects: 11
Study 15195000 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior and septal wall [123I]-MIBG uptake on 4 hour SPET
Number of subjects: 11
Study 15195000 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-MIBI SPET rest regional uptake
Number of subjects: 11
Study 11329735 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestions to improve informed consent processes in clinical trials
Number of subjects: 0
Study 9891830 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty with high Lp (a) levels (above 0.30 g/l)
Number of subjects: 59
Study 9891830 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease without restenosis
Number of subjects: 59
Study 9891830 — intervention group
Group type: EXPERIMENTAL
Intervention: No angiographic or clinical restenosis
Number of subjects: 59
Study 7573093 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular nicotinic acid
Number of subjects: 110
Study 7573093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release nicotinic acid
Number of subjects: 110
Study 2248105 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecolyzer Model 210
Number of subjects: 29
Study 2248105 — intervention group
Group type: COMPARATOR
Intervention: Ecolyzer Series 2000
Number of subjects: 29
Study 7241682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinoxacin 500 mg twice daily for 10 days
Number of subjects: 40
Study 7241682 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole 160-800 mg twice daily for 10 days
Number of subjects: 40
Study 7241682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinoxacin
Number of subjects: 40
Study 7241682 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 40
Study 7241682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study 30427227 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop height of 20 cm
Number of subjects: 239
Study 30427227 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop height of 35 cm
Number of subjects: 239
Study 30427227 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop height of 50 cm
Number of subjects: 239
Study 30427227 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop heights (20, 35, 50 cm)
Number of subjects: 239
Study 28646784 — intervention group
Group type: EXPERIMENTAL
Intervention: 30min of morning light therapy (5,000lx; blue-enriched polychromatic light, 17,000K)
Number of subjects: 48
Study 28646784 — intervention group
Group type: COMPARATOR
Intervention: Sham session (200lx, polychromatic light, 5,000K)
Number of subjects: 48
Study 26216608 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal balloon autoinflation 3 times daily for 1-3 months plus usual care
Number of subjects: 320
Study 26216608 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 320
Study 22935321 — intervention group
Group type: EXPERIMENTAL
Intervention: High blueberry dose (75 g)
Number of subjects: 14
Study 22935321 — intervention group
Group type: EXPERIMENTAL
Intervention: Low blueberry dose (35 g)
Number of subjects: 14
Study 22935321 — intervention group
Group type: COMPARATOR
Intervention: Control (ascorbic acid and sugar matching high blueberry dose)
Number of subjects: 14
Study 22044987 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-extremity rehabilitation robotic training
Number of subjects: 27
Study 20038285 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Number of subjects: 0
Study 20038285 — intervention group
Group type: COMPARATOR
Intervention: ASA
Number of subjects: 0
Study 20038285 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 0
Study 20038285 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study 20038285 — intervention group
Group type: COMPARATOR
Intervention: ASA with dipyridamole
Number of subjects: 0
Study 17197849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4
Number of subjects: 36
Study 17197849 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 36
Study 17197849 — intervention group
Group type: COMPARATOR
Intervention: Poligeline
Number of subjects: 36
Study 14747230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 50
Study 11133899 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normoxic exercise
Number of subjects: 32
Study 11133899 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoxic exercise
Number of subjects: 32
Study 11133899 — intervention group
Group type: COMPARATOR
Intervention: Intermittent training in normoxia
Number of subjects: 32
Study 11133899 — intervention group
Group type: COMPARATOR
Intervention: Intermittent training in hypoxia
Number of subjects: 32
Study 9754896 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot pump mechanical compression
Number of subjects: 40
Study 9754896 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 40
Study 8141279 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (0.03 mg.kg ideal body wt‐1.day‐1)
Number of subjects: 9
Study 2183716 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tobramycin (40 mg every 8 h)
Number of subjects: 85
Study 2183716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (endotracheally every 8 h)
Number of subjects: 85
Study 2183716 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tobramycin
Number of subjects: 85